Table 4.
Cox Regression Results Indicating Interaction Effect Between Intervention and Medication
| Outcome | Model 3* | Model 4*,† | ||
|---|---|---|---|---|
| PA to HE HR (95% CI) | p for Interaction | PA to HEHR (95% CI) | p for Interaction | |
| MMD | ||||
| ACEi use | 0.76 (0.57, 1.02) | .214 (2 df) | 0.80 (0.59, 1.07) | .175 (2 df) |
| Other antihypertensive use | 0.76 (0.60, 0.97) | 0.78 (0.61, 0.99) | ||
| No antihypertensive use | 1.19 (0.75, 1.87) | 1.25 (0.80, 1.98) | ||
| Persistent MMD | ||||
| ACEi use | 0.57 (0.39, 0.84) | .180 (2 df) | 0.58 (0.39, 0.86) | .127 (2 df) |
| Other antihypertensive use | 0.76 (0.55, 1.06) | 0.79 (0.56, 1.11) | ||
| No antihypertensive use | 1.18 (0.59, 2.36) | 1.31 (0.65, 2.63) | ||
Notes: ACE = angiotensin-converting enzyme; CI = confidence interval; df = degrees of freedom; HE, health education; HR = hazard ratio; MMD = major mobility disability; PA = physical activity.
*Hazards for disability outcomes stratified by sex and clinical site.
†Includes adjustment for baseline covariates including Short Physical Performance Battery score and a composite index of comorbid conditions reported previously (13,22).